MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate multiple intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Key demo aims were being To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though one of many exploratory https://edwinfkpsv.blogpixi.com/31195972/a-secret-weapon-for-m3541